Utama › Kanser (semua jenis) › Iowa › Cedar Rapids
Kajian klinikal Kanser (semua jenis) di Cedar Rapids, IA
15 kajian untuk Kanser (semua jenis) sedang mencari peserta di lokasi dalam dan sekitar Cedar Rapids (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Mengambil pesertaFasa 1
- University of Iowa Health, Iowa City · 25 mi jauh
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Mengambil pesertaKajian pemerhatian
- The State University of Iowa, Iowa City · 25 mi jauh
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Mengambil pesertaFasa 1/2
- University of Iowa Hospitals ( Site 4017), Iowa City · 25 mi jauh
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Mengambil pesertaFasa 3
- Holden Comprehensive Cancer Center, Iowa City · 25 mi jauh
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Mengambil pesertaFasa 1/2
- University of Iowa Health Care Holden Comprehensive Cancer Center ( Site 3017), Iowa City · 25 mi jauh
Collection of Tissue Samples for Cancer Research
Mengambil pesertaKajian pemerhatian
- University of Iowa, Iowa City · 25 mi jauh
Lurbinectedin in FET-Fused Tumors
Mengambil pesertaFasa 1/2
- University of Iowa Hospitals and Clinics, Iowa City · 25 mi jauh
Project: Every Child for Younger Patients With Cancer
Mengambil pesertaKajian pemerhatian
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi jauh
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Mengambil pesertaFasa 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi jauh
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Mengambil pesertaFasa 1
- University of Iowa Hospitals, Iowa City · 25 mi jauh
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- University of Iowa, Iowa City · 25 mi jauh
Molecular Genetics Studies of Cancer Patients and Their Relatives
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Mercy Hospital, Cedar Rapids
GEMINI-NSCLC: NSCLC Biomarker Study
Mengambil pesertaKajian pemerhatian
- University of Iowa, Iowa City · 25 mi jauh
Beat Childhood Cancer Specimen Banking and Data Registry
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- University of Iowa, Iowa City · 25 mi jauh
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Iowa City · 25 mi jauh
Kajian Kanser (semua jenis) di bandar lain
- Houston, TX121 kajian
- New York City, NY110 kajian
- Boston, MA86 kajian
- Los Angeles, CA73 kajian
- Nashville, TN65 kajian
- Philadelphia, PA59 kajian
- Durham, NC58 kajian
- Washington, DC58 kajian
- Chicago, IL51 kajian
- Seattle, WA49 kajian
- Atlanta, GA49 kajian
- Arlington, VA48 kajian
Kajian lain di Cedar Rapids
- Kanser Paru-paru Bukan Sel Kecil20 kajian
- Kanser Payudara17 kajian
- Leukemia Mieloid Akut16 kajian
- Mieloma Pelbagai15 kajian
- Kanser Paru-paru14 kajian
- Kanser Kolorektal13 kajian
- Kanser Prostat12 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher12 kajian
- Melanoma10 kajian
- Strok10 kajian
- Kanser Metastatik9 kajian
- Kanser Endometrium9 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.